Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AL-39256, 1% · 1 trial · 2 indications
| Arm | Type | Description |
|---|---|---|
| AL-39256 | EXPERIMENTAL | AL-39256 Ophthalmic Suspension, 1%, 1 drop in the study eye(s) at 8 AM from the morning bottle and 1 drop in the study eye(s) at 8 PM from the evening bottle for 4 weeks. |
| XALATAN | ACTIVE_COMPARATOR | Latanoprost Ophthalmic Solution, 0.005%, 1 drop in the study eye(s) at 8 PM from the evening bottle (morning bottle contained vehicle and was dosed 1 drop in the study eye(s) at 8 AM) for 4 weeks. |
| Vehicle | PLACEBO_COMPARATOR | Inactive ingredients, 1 drop in the study eye(s) at 8 AM from the morning bottle and 1 drop in the study eye(s) at 8 PM from the evening bottle for 4 weeks. |
| Name | Type | Description |
|---|---|---|
| AL-39256 Ophthalmic Suspension, 1% | DRUG | - |
| Latanoprost Ophthalmic Solution, 0.005% | DRUG | - |
| Vehicle | DRUG | Inactive ingredients used as a placebo comparator |
Inclusion Criteria: * Diagnosed with open-angle glaucoma or ocular hypertension. * Other protocol-defined inclusion criteria may apply. Exclusion Criteria: * Females of childbearing potential. * Other protocol-defined exclusion criteria may apply.
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Glaukos Corp | GKOS | 3 | PHASE4 | Travoprost Intraocular |
| Amneal Pharmaceuticals, Inc. Class A | AMRX | 1 | PHASE4 | Test - Bimatoprost 0.01%, Reference - LUMIGAN |
| AbbVie, Inc. | ABBV | 1 | PHASE4 | Bimatoprost |
| United Therapeutics Corporation | UTHR | 1 | PHASE4 | Nicotinomide |
| Alcon AG | ALC | 3 | PHASE4 | Undisclosed |
AL-39256 is an investigational small molecule being developed for the treatment of open-angle glaucoma. It is formulated as a 1% ophthalmic solution and is intended to lower intraocular pressure in patients with open-angle glaucoma or ocular hypertension.
AL-39256 is being developed by Alcon Inc., a company traded on the New York Stock Exchange under the ticker symbol ALC. Alcon is a global medical device and pharmaceutical company focused on eye care, including ophthalmology products.
AL-39256 is in Phase 2 clinical development. It has completed a Phase 2 trial, and it remains an investigational drug that has not been approved by regulatory authorities. Further clinical development would be required before any potential approval.
AL-39256 has been studied in one completed Phase 2 clinical trial, identified as NCT00761709. This trial evaluated the safety and intraocular pressure-lowering efficacy of AL-39256 in patients with open-angle glaucoma or ocular hypertension. The study enrolled 104 participants and was randomized, double-blind, and placebo-controlled.
AL-39256 is the primary name for this investigational drug. No alternative names have been reported for this compound in the available clinical trial information. It is a distinct small molecule being developed by Alcon for ophthalmic use.